TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Rechon Life Science AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
48,546
|
43,794
|
34,889 |
| Financial expenses |
343
|
282
|
116 |
| Earnings before taxes |
5,151
|
5,086
|
5,415 |
| EBITDA |
7,127
|
7,093
|
6,994 |
| Total assets |
42,346
|
32,834
|
29,380 |
| Current assets |
23,286
|
18,474
|
15,121 |
| Current liabilities |
12,509
|
9,091
|
7,173 |
| Equity capital |
21,717
|
18,291
|
15,247 |
| - share capital |
2,398
|
2,482
|
2,475 |
| Employees (average) |
286
|
249
|
212 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
51.3%
|
55.7%
|
51.9% |
| Turnover per employee |
170
|
176
|
165 |
| Profit as a percentage of turnover |
10.6%
|
11.6%
|
15.5% |
| Return on assets (ROA) |
13.0%
|
16.3%
|
18.8% |
| Current ratio |
186.2%
|
203.2%
|
210.8% |
| Return on equity (ROE) |
23.7%
|
27.8%
|
35.5% |
| Change turnover |
6,242
|
8,803
|
7,423 |
| Change turnover % |
15%
|
25%
|
27% |
| Chg. No. of employees |
37
|
37
|
28 |
| Chg. No. of employees % |
15%
|
17%
|
15% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.